Sigilon Therapeutics Operating Income

Sigilon Therapeutics (SGTX) currently reports a operating income of $-31M as of June 2023. That compares with $-65M in the prior-year period — up 52.2% year over year. Use the charts on this page to explore Sigilon Therapeutics's operating income history and peer comparisons.

Sigilon Therapeutics's operating income increased from $-65M to $-31M — a 52.2% year-over-year increase (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Sigilon Therapeutics reported $-31M in operating income as of June 2023. That compares with $-65M in the prior-year period — up 52.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-31M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Sigilon Therapeutics, and consider following SGTX for alerts when major investors trade the stock.

Sigilon Therapeutics is classified in the Healthcare sector. On operating income, it currently shows $-31M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SGTX with unrelated industries.